MMP-14 Potency Assay for Predictive MSC Therapy Evaluation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease (AD) and hypoplastic left heart syndrome (HLHS) are inadequate, with high mortality rates and limited therapeutic options, and there is a lack of effective methods to predict AD onset and progression due to complex pathology and heterogeneous genetic factors.
Innovation Solution
Administration of allogeneic mesenchymal stem cells (MSCs) to treat AD and HLHS, with methods to evaluate their efficacy through biomarker measurement and MRI analysis, and inhibition of MMP-14 to assess potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Alzheimer's disease and hypoplastic left heart syndrome are used, then treatment options are limited, but mortality rates remain high and therapeutic efficacy is insufficient
Solution Approach 1:
The patent uses mesenchymal stem cells (MSCs) as intermediary therapeutic agents that mediate treatment between the administered cells and the pathological conditions. These MSCs serve as living mediators that can differentiate, secrete therapeutic factors, and modulate immune responses, thereby improving therapeutic efficacy while reducing mortality in AD and HLHS treatments
Solution Approach 2:
The patent employs MMP-14 inhibition as a measurable parameter change to assess MSC potency and predict treatment outcomes. By monitoring MMP-14 activity levels as a quantitative parameter, the patent optimizes treatment efficacy and reduces mortality through data-driven therapeutic decisions
2Measurement precision
If biomarker measurement and MRI analysis are used to evaluate MSC treatment, then treatment effectiveness can be measured, but assessment complexity increases
Solution Approach 1:
The patent segments the complex treatment evaluation into distinct measurable components: MMP-14 inhibition activity, specific biomarker levels (TIMP-2, VEGF-A, IL-6, IL-8), and MRI morphological changes. This segmentation allows systematic assessment of MSC potency and treatment effectiveness through multiple independent measurements rather than a single complex assessment
3Measurement precision
If MMP-14 inhibition is used to assess MSC potency, then therapeutic potential can be predicted, but assay complexity increases
Solution Approach 1:
The patent uses MMP-14 inhibition as an intermediary measurement that simplifies potency assessment. Instead of directly measuring complex cellular functions, the assay measures MMP-14 enzymatic activity as a surrogate marker, which correlates with overall MSC therapeutic potential and can be detected using standardized biochemical assays
Data Source
AI summary
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease and hypoplastic left heart syndrome (HLHS) with allogeneic mesenchymal stem cells (MSCs). The methods of treatment involve an administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers.